Physician profile
John E Herzenberg
NPI 1922041557
$745,876.80
in general payments reported to CMS, 2019-2025
16 companies · $301K in 2025
The $301K reported for 2025 was more than what 99% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,265 · 2020: $794 · 2021: $115K · 2022: $5,730 · 2023: $86K · 2024: $235K · 2025: $301K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $589K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Travel and Lodging: $10K · Consulting Fee: $7,250 · Food and Beverage: $681.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $588,752.86 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,000.00 |
| Travel and Lodging | $10,329.85 |
| Consulting Fee | $7,250.00 |
| Food and Beverage | $681.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $623,139.38 | 2019-2025 | Taylor Spatial Frame, Smart Tsf, Spatial Frame |
| Synthes Gmbh | $109,430.09 | 2021-2022 | |
| Orthopediatrics Canada Ulc | $7,950.10 | 2024-2025 | |
| Nuvasive Specialized Orthopedics, INC. | $1,947.34 | 2019-2023 | Precice Intramedullary Limb Lengthening System |
| Globus Medical, INC. | $1,531.32 | 2021-2025 | Autobahn, Precice® Intramedullary Limb Lengthening System |
| Wishbone Medical INC. | $1,410.00 | 2019-2023 | Cat Kit |
| Depuy Synthes Sales INC. | $131.08 | 2021 | |
| Supreme Orthopedic Systems, LLC | $125.00 | 2021 | |
| Orthopediatrics Corp. | $98.67 | 2019-2025 | |
| Abbvie INC. | $54.64 | 2022-2023 | |
| Cerapedics INC. | $16.61 | 2021 | |
| Paratek Pharmaceuticals, INC. | $16.33 | 2021 | |
| Heraeus Medical, LLC. | $14.13 | 2019 | |
| Biomarin Pharmaceutical INC. | $12.11 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$13,600.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Herzenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.